Drugs / HyperAcute Renal
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02035358 | May 2015 → Jan 2017 | clear cell renal carcinoma | NewLink Genetics Corporation | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HyperAcute Renal | “HyperAcute Renal (HAR) immunotherapy exploits a naturally occurring barrier to xenotransplantation and zoonotic infections in humans to immunize patients against metastatic...” PMID 32043778 ↗ Sep 2019 |
| Action | Deplete | “triggering the immune system to attack and destroy micrometastatic disease” NCT02035358 ↗ |
| Modality | Cell therapy | “cellular immunotherapy” NCT02035358 ↗ |
| Route | Other | “Cells will be injected intradermally every 1 week x 4 weeks” NCT02035358 ↗ |